Breast Cancer
Conditions
Brief summary
To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions. To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis
Interventions
DEVICEELISA
Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).
Sponsors
Marina Hanna Thabet Ghobrial
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
\- Females aged (40 ± 20 years) who did not receive any chemotherapy or surgical treatment and they will be divided as follow: Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients.
Exclusion criteria
* 1- Female patients with any other type of malignant or benign tumors. 2- Past history of chemotherapy or surgical treatment of cancer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic value of Asprosin as a biomarker in breast cancer | Baseline | Evaluation of the clinical utility of measurement of asprosin as a non invasive biomarker in the diagnosis of breast cancer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic value of Asprosin as a biomarker in breast cancer | Baseline | Comparing asproin and the routine markers (CEA, CA15-3) as biomarkers for diagnosis of breast cancer. |
Contacts
Primary ContactMarina Hanna Thabet
Backup ContactEman Mohamed Abdelrahman
Outcome results
None listed